Mereo BioPharma Group PLC (NASDAQ: MREO) is a clinical-stage biopharmaceutical company that develops investigational drug candidates targeting rare and specialty diseases. The company does not yet generate product revenue and funds operations through capital raises, out-licensing proceeds, and external financing, including convertible loan notes. Mereo's 10-K filed March 19, 2026 (accession 000119312526115226) discloses that the company requires additional funding to support continuing operations, a going-concern condition flagged by auditors in the FY2025 filing. Cash outflows are classified as net cash used in operating and investing activities for both the years ended December 31, 2025 and December 31, 2024. The company is incorporated in the United Kingdom and is subject to regulatory oversight in the U.S., EU, and U.K., reflecting a cross-border clinical development footprint. No product revenue, customer concentration data, or segment breakdown is disclosed in the available filing excerpts.

Revenue model

Pre-revenue clinical-stage company. Cash inflows disclosed in the FY2025 filing include proceeds from out-licensing and financing activities including convertible loan notes. No product sales revenue is reported for the years ended December 31, 2025 or December 31, 2024.

Products and services

Investigational pharmaceutical drug candidates targeting rare and specialty diseases. Specific product names are not identified in the available filing excerpts.

Customers and end markets

No commercial customers are disclosed. End markets are rare and specialty disease patients, with regulatory and reimbursement exposure to Medicare, Medicaid, private third-party payors, and equivalent programs in the EU and U.K., as described in the FY2025 10-K compliance disclosures.

Value-chain role

Clinical-stage drug developer. The company conducts research and development, engages third-party manufacturers for investigational products, and pursues out-licensing arrangements. It does not manufacture or commercialize approved products based on available filing excerpts.

Geographic exposure

Operations span the U.S., EU, and U.K. The company is incorporated in the United Kingdom and is subject to U.S. FDA, EU, and U.K. regulatory frameworks, as well as data protection and trade control laws across those jurisdictions, per the FY2025 10-K.

Source: SEC 10-K, filed 2026-03-19

Industry: Pharmaceutical Preparations Peers: Achilles Therapeutics plc F-star Therapeutics, Inc. Tiziana Life Sciences Ltd Barinthus Biotherapeutics PLC